Immunocore
IMCR
120 hedge funds and large institutions have $2.12B invested in Immunocore in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 50 increasing their positions, 25 reducing their positions, and 16 closing their positions.
659% more call options, than puts
Call options by funds: $27.2M | Put options by funds: $3.58M
100% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 25
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
31% more capital invested
Capital invested by funds: $1.61B → $2.12B (+$501M)
10% more funds holding
Funds holding: 109 → 120 (+11)
5.47% more ownership
Funds ownership: 67.98% → 73.44% (+5.5%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$59.4M |
| 2 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$29.8M |
| 3 |
RI
RTW Investments
New York
|
+$21.7M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.3M |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
+$8.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$11.1M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$9.89M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$8.4M |
| 4 |
Millennium Management
New York
|
-$6.71M |
| 5 |
D.E. Shaw & Co
New York
|
-$5.39M |
IMCR Hedge Fund Activity: Q2 2023 in Review
120 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q2 2023, worth a combined $2.12B — up 31% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new IMCR positions and 16 closed out — a net gain of 13 holders — while 50 added to existing stakes and 25 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $59.4M. The largest seller was Avidity Partners Management, cutting an estimated $11.1M.
- 120 institutional investors held Immunocore (IMCR) as of Q2 2023, up from 109 in Q1 2023.
- Funds reported $2.12B of Immunocore stock for Q2 2023, up 31% quarter-over-quarter.
- 29 funds opened new Immunocore positions in Q2 2023 and 16 closed out, a net change of +13 holders.
- The largest Immunocore buyer in Q2 2023 was T. Rowe Price Associates, an estimated $59.4M added.
- The largest Immunocore seller in Q2 2023 was Avidity Partners Management, an estimated $11.1M sold.
Based on aggregated 13F filings for Q2 2023.